All Pharma News
Salarius Reports Fourth Quarter and Full Year 2023 Financial Results

Salarius Reports Fourth Quarter and Full Year 2023 Financial Results
GLOBENEWSWIRE
22 Mar 2024
Share Share
Salarius Provides Update on Review Process to Support Seclidemstat Trials

Salarius Provides Update on Review Process to Support Seclidemstat Trials
GLOBENEWSWIRE
22 Feb 2024
Share Share
Salarius Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Issued U.S. Patent for Next-Generation Targeted Protein Degraders
GLOBENEWSWIRE
16 Jan 2024
Share Share
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius` Seclidemstat to Treat Hematologic Cancers
GLOBENEWSWIRE
03 Jan 2024
Share Share
Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program

Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program
GLOBENEWSWIRE
07 Nov 2023
Share Share
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results
GLOBENEWSWIRE
10 Aug 2023
Share Share
Cash-strapped Salarius lays off over 50% of staff, mulls options

Cash-strapped Salarius lays off over 50% of staff, mulls options
James Waldron FIERCE BIOTECH
10 Aug 2023
Share Share
Salarius Announces Plans to Explore Measures to Extend its Resources

Salarius Announces Plans to Explore Measures to Extend its Resources
GLOBENEWSWIRE
08 Aug 2023
Share Share
Salarius Receives FDA Clearance of SP-3164 IND application to Begin Ph 1 Trial

Salarius Receives FDA Clearance of SP-3164 IND application to Begin Ph 1 Trial
GLOBENEWSWIRE
11 Jul 2023
Share Share
Salarius Presents SP-3164 Targeted Protein Degrader Preclinical Data

Salarius Presents SP-3164 Targeted Protein Degrader Preclinical Data
GLOBENEWSWIRE
12 Jun 2023
Share Share